CLSD.NASDAQClearside Biomedical, INC

10-Q: Clearside Biomedical Reports Q1 2025 Financial Results, Cites Progress in CLS-AX Development

Sentiment:

Quarterly Report

📋All filings for Clearside Biomedical, INC
🔒Login to Follow

Clearside Biomedical announces its Q1 2025 financial results, highlighting a net loss of $8.2 million and progress in its CLS-AX clinical program for wet AMD.

Capital raiseThe company will continue to need to obtain additional financing to fund future operations.The company is actively pursuing options to fund its Phase 3 CLS-AX program, including potentially partnering with one or more third parties.The company may finance future cash needs through public or private equity offerings, license agreements, debt financings or restructurings, collaborations, strategic alliances and marketing or distribution arrangements.
Worse than expectedThe company reported a net loss of $8.2 million and has an accumulated deficit of $363.5 million.The company's auditors have raised substantial doubt regarding the company's ability to continue as a going concern.The company anticipates needing additional capital to fund future operations.

Summary

  • Clearside Biomedical reported a net loss of $8.2 million for the three months ended March 31, 2025, compared to a net loss of $11.8 million for the same period in 2024.
  • License and other revenue increased to $2.3 million, driven by milestones from Arctic Vision and sales of SCS Microinjector kits.
  • Research and development expenses decreased to $4.5 million due to the completion of the ODYSSEY Phase 2b clinical trial for CLS-AX.
  • The company's cash and cash equivalents totaled $13.6 million as of March 31, 2025.
  • Clearside expects its current cash resources to fund operations into the fourth quarter of 2025.
  • The company is actively pursuing options to fund its Phase 3 CLS-AX program, including potential partnerships.
  • Clearside plans to initiate Phase 3 clinical trials for CLS-AX in the second half of 2025, pending funding.
  • The company is also evaluating small molecules for the potential treatment of geographic atrophy (GA).
  • The company has strategic partnerships with Bausch + Lomb, Arctic Vision, REGENXBIO, Aura Biosciences and BioCryst Pharmaceuticals, Inc.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While there's progress in revenue and R&D cost management, the company's going concern status and need for additional funding weigh heavily.

Positives

  • The net loss decreased from $11.8 million in Q1 2024 to $8.2 million in Q1 2025.
  • License and other revenue increased significantly, driven by milestones from Arctic Vision.
  • Research and development expenses decreased due to the completion of the ODYSSEY trial.
  • The company is preparing to initiate Phase 3 trials for CLS-AX in the second half of 2025.
  • The company is actively pursuing options to fund its Phase 3 CLS-AX program, including potential partnerships.

Negatives

  • The company reported a net loss of $8.2 million for the quarter.
  • The company has an accumulated deficit of $363.5 million.
  • The company's cash and cash equivalents decreased to $13.6 million.
  • The company anticipates needing additional capital to fund future operations.
  • The company's auditors have raised substantial doubt regarding the company's ability to continue as a going concern.

Risks

  • The company's ability to continue as a going concern is in doubt due to recurring losses and the need for additional financing.
  • The company's plans are contingent on raising additional capital, which may not be available on favorable terms or at all.
  • The successful development and commercialization of product candidates are subject to numerous risks and uncertainties.
  • Macroeconomic conditions, including rising inflation and economic uncertainty, could negatively affect the company's business and results of operations.
  • The company is dependent on its licensees to successfully commercialize XIPERE.

Future Outlook

Clearside expects its current cash resources to fund operations into the fourth quarter of 2025 and plans to initiate Phase 3 clinical trials for CLS-AX in the second half of 2025, contingent on securing additional funding.

Management Comments

  • Management expects clinical trial expenses to increase in 2025 due to the planned Phase 3 clinical program of CLS-AX.
  • Management believes that GA is primarily a choroidal disease and that delivery of small molecules via suprachoroidal injection enables comprehensive drug coverage of both the retina and choroid, while also potentially minimizing systemic and anterior segment side effects.

Industry Context

Clearside is operating in the competitive biopharmaceutical industry, focusing on novel drug delivery methods for ophthalmic diseases. The company's suprachoroidal space (SCS) injection platform aims to improve targeted drug delivery to the back of the eye, potentially offering advantages over traditional intravitreal injections. The company faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for retinal diseases such as wet AMD and geographic atrophy.

Comparison to Industry Standards

  • The company's cash position of $13.6 million is relatively low compared to other publicly traded biopharmaceutical companies in clinical development.
  • The company's reliance on licensing agreements and milestone payments for revenue generation is common in the industry, but also carries inherent risks.
  • The company's focus on suprachoroidal drug delivery is a differentiating factor, but the technology's long-term success will depend on clinical trial outcomes and commercial adoption.
  • The company's partnerships with Bausch + Lomb and Arctic Vision are strategic moves to leverage external expertise and resources for commercialization.

Related Party Transactions

  • A member of the Company's Board of Directors was the chief executive officer of a company that is a vendor of the Company until January 2025.
  • The chair of the board of directors of BioCryst also serves on the Company's Board of Directors.

Stakeholder Impact

  • Shareholders face potential dilution from future equity offerings.
  • Employees face uncertainty due to the company's financial situation and potential need for cost-cutting measures.
  • Licensees and partners are dependent on Clearside's ability to secure funding and advance its product candidates.
  • Patients may benefit from the successful development and commercialization of Clearside's therapies.

Next Steps

  • Initiate Phase 3 clinical trials for CLS-AX in the second half of 2025, contingent on securing funding.
  • Continue evaluating small molecules for the potential treatment of geographic atrophy (GA).
  • Pursue options to fund the Phase 3 CLS-AX program, including potential partnerships.
  • Seek regulatory approvals in additional regions for XIPERE for the treatment of macular edema associated with uveitis.

Key Dates

DateDescription
May 26, 2011Clearside Biomedical, Inc. incorporated in the State of Delaware.
August 8, 2022The Company, through its wholly owned subsidiary Clearside Royalty LLC, entered into the Purchase and Sale Agreement with entities managed by HealthCare Royalty Management, LLC.
July 1, 2023Date after which Sublicensee payments are subject to revised Emory License Agreement terms.
May 2023The Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co.
November 1, 2023The Company entered into the BioCryst License Agreement.
December 22, 2023The Company, through its wholly owned subsidiary Royalty Sub, entered into the Letter Agreement with the Agent amending the Purchase and Sale Agreement.
December 31, 2024Date of Consolidated Balance Sheets.
January 1, 2025Date before which Sublicensee payments are subject to revised Emory License Agreement terms.
January 31, 2024The Company entered into a fourth amendment to the license agreement with Emory University and Georgia Tech Research Corporation.
February 6, 2024The Company entered into a securities purchase agreement with institutional investors and an existing stockholder, pursuant to which the Company issued and sold, in a registered direct offering.
March 27, 2025Filing date of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
March 31, 2025End of the quarterly period for this report; date of Consolidated Balance Sheets.
May 12, 2025Date as of which the registrant had 77,708,536 shares of common stock outstanding.
May 15, 2025Filing date of this report.
August 9, 2029Expiration date of the Warrants issued in the February 6, 2024 registered direct offering.

Keywords

Clearside Biomedical, financial results, CLS-AX, wet AMD, suprachoroidal, XIPERE, Arctic Vision, Bausch + Lomb, clinical trials, revenue, net loss, cash, funding, biopharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.